Growth factor concentrate composition

A stable growth factor concentrate composition, devoid of red blood cells and neutrophils, combined with exosomes and vitamin C serum, addresses the limitations of existing PRP kits by enhancing skin rejuvenation and anti-aging outcomes without adverse effects.

WO2024236603A1PCT designated stage expired Publication Date: 2024-11-21KHORAKIWALA ZAHABIYA
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
PCT/IN2024/050574
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-18
Filing Date
2024-05-17
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Commercially available platelet-rich plasma (PRP) preparation kits do not effectively remove white blood cells and red blood cells, which can lead to reduced healing effects and pain post-treatment due to the presence of these cells in the growth factor solutions, necessitating the development of an acellular growth factor solution without red blood cells and neutrophils.

Method used

A stable growth factor concentrate composition comprising growth factors and exosomes, isolated from human blood samples, specifically designed to be free of red blood cells and neutrophils, which works synergistically with vitamin C serum to enhance therapeutic and cosmetic treatments.

Benefits of technology

The composition demonstrates significant improvements in skin anti-aging parameters, such as wrinkles, texture, and moisture, with no adverse events reported, indicating effective and safe use for skin rejuvenation and anti-aging treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000015_0001
    Figure IMGF000015_0001
  • Figure IMGF000015_0002
    Figure IMGF000015_0002
  • Figure IMGF000016_0001
    Figure IMGF000016_0001
Patent Text Reader

Abstract

The invention relates to the technical field of regenerative medicine, in particular to a stable growth factor concentrate composition comprising growth factors and exosomes Furthermore, this invention relates to a stable autologous growth factor concentrate composition and a stable face serum composition. This invention also relates to a uses of growth factor concentrate composition in various therapeutic and cosmetic treatments.
Need to check novelty before this filing date? Find Prior Art

Description

[0001]GROWTH FACTOR CONCENTRATE COMPOSITION RELATED PATENT APPLICATIONS This application claims priority to and benefit of the Indian Patent Application No. 202321034767 filed on May 18, 2023, the disclosures of which are incorporated herein by reference in its entirety as if fully rewritten herein. Field of the invention The invention relates to the technical field of regenerative medicine, in particular to a stable growth factor concentrate composition comprising growth factors and exosomes. This invention also relates to a uses of growth factor concentrate composition in various therapeutic and cosmetic treatments. Background of the invention At present, significant advances have been made in regenerative medicines with good therapeutic prospects for treating different diseases. Growth factors are a group of naturally occurring proteins or steroid hormones that are capable of stimulating cellular growth, proliferation and cellular differentiation. Growth factors are important for regulating a variety of cellular processes and play an important part in maintaining healthy skin structure and function. In this respect, reference is made to the publication by Chandrashekar B, Sarangi K, Mastim M A, and Vijay Sharma et al. (May 21, 2022) A Prospective Multicenter Study to Evaluate the Safety and Efficacy of the Topical Application of MYOWNN™, an Autologous Growth Factor Concentrate (AGFC) Serum, in Anti-Aging. Cureus 14(5): e25190. DOI 10.7759 / cureus.25190. To obtain the maximum benefit from growth factors, it is usually thought that platelets should be maximally concentrated; however, if white blood cells (WBCs) are simultaneously concentrated in the platelet fraction, the positive effects of growth factors may be reduced. Several studies demonstrate that the presence of WBCs and red blood cells (RBCs) are detrimental to the healing effects demonstrated by the released growth factors. Most commercially available platelet-rich plasma (PRP) preparation kits do not remove RBCs and WBCs which may cause pain and inflammation post-treatment. Therefore, do not harness the use of an acellular growth factor solution that has several advantages. It is necessary to provide acellular growth factors self-provided by the subject in need without red blood cells (RBCs) and neutrophils. Summary of the invention The present invention provides a growth factor concentrate composition for use in various therapeutic and cosmetic treatments of a subject in need thereof, in which the growth factor concentrate composition comprises growth factors and exosomes, preferably without red blood cells (RBCs) and without neutrophils. The present inventors have surprisingly observed that the presence of exosomes in the growth factor concentrate composition works synergistically with growth factors. In a first aspect, the present disclosure provides a stable growth factor concentrate composition comprising: (a) growth factors; and (b) exosomes. In an embodiment of the first aspect described herein, the exosomes in the growth factor concentrate composition are growth factor concentrate (GFC) derived exosomes. In another embodiment of the first aspect described herein, the growth factors and exosomes in the growth factor concentrate composition are isolated from human blood samples from healthy volunteers. In another embodiment of the first aspect described herein, the growth factors in the growth factor concentrate composition are acellular growth factors and are free of red blood cells (RBCs) and neutrophils. In another embodiment of the first aspect described herein, the analysed growth factors in the growth factor concentrate composition are Platelet Derived Growth Factor (PDGF), Transforming Growth Factor Beta (TGF-B), and Vascular Endothelial Growth Factor (V EGF). In another embodiment of the first aspect described herein, the growth factor concentrate composition further comprises a serum. In another embodiment of the first aspect described herein, the growth factor concentrate composition further comprises a serum and the serum is vitamin C serum. In another embodiment of the first aspect described herein, the growth factor concentrate composition further comprises a vitamin C serum wherein the vitamin C serum in the growth factor concentrate composition comprises various ingredients. In another embodiment of the first aspect described herein, the growth factor concentrate composition further comprises a vitamin C serum, wherein the vitamin C serum in the growth factor concentrate composition comprises various ingredients that are one or more of Aqua, Glycerine, Ethyl Ascorbic Acid, Papaya Extract, Orange Extract, Licorice Extract, Niacinamide, Hyaluronic Acid, Citric Acid, Vitamin E Acetate, Xanthan Gum, Allantoin, Hydroxyethyl Cellulose, D Panthenol and Aloe Vera Extract. In a second aspect, the present disclosure provides a stable autologous growth factor concentrate composition comprising: (a) growth factors; (b) exosomes; and (c) vitamin C serum. In a third aspect, the present disclosure provides a stable face serum composition comprising: (a) growth factors; (b) exosomes; and (c) vitamin C serum. Embodiments disclosed in the context of the first aspect are also applicable to the second and third aspect, unless specified otherwise. In another embodiment described herein, the composition according to the first to third aspect is stable for one or more from the following: (a) at least 12 months at 4°C, (b) at least 12 months at 25°C ± 2°C and a relative humidity of 60% ± 5 %, (c) at least 9 months at 30°C ± 2°C and a relative humidity of 65% ± 5 %, or (d) at least 6 months at 40°C ± 2°C and a relative humidity of 70% ± 5 %. In another embodiment according to the first to third aspect described herein, the exosomes are present at a concentration of 1x109exosomes / ml to 4.5 x1012exosomes / ml. In another embodiment according to the first to third aspect described herein, the exosomes are present at a concentration of 3.13×1010exosomes / ml to 4.25×1012exosomes / ml. In another embodiment according to the first to third aspect described herein, the exosomes are present in the composition at a concentration of about 3.13×1010exosomes / ml, 1.62×1011exosomes / ml, 2.30×1011exosomes / ml, 2.41×1011exosomes / ml, 2.59×1011exosomes / ml, 2.99×1011exosomes / ml, 3.06×1011exosomes / ml, 3.12×1011exosomes / ml, 3.25×1011exosomes / ml, 3.69×1011exosomes / ml, 4.07×1011exosomes / ml, 4.22×1011exosomes / ml, 4.42×1011exosomes / ml, 4.55×1011exosomes / ml, 4.56×1011exosomes / ml, 5.17×1011exosomes / ml, 5.50×1011exosomes / ml, 5.53×1011exosomes / ml, 5.73×1011exosomes / ml, 5.92×1011exosomes / ml, 6.62×1011exosomes / ml, 6.91×1011exosomes / ml, 8.25×1011exosomes / ml, 2.68×1012exosomes / ml, or 4.25×1012exosomes / ml. In a fourth aspect, the present disclosure provides a composition according to the first to third aspect for use as a medicament. In a fifth aspect, the present disclosure provides a composition according to the first to third aspect for use in maintaining healthy skin structure and function, for use in skin anti-aging or rejuvenation, or in the treatment of skin diseases. In a sixth aspect, the present disclosure provides a method of cosmetic treatment comprising applying a composition according to the first to third aspect to the skin of a human subject. In a seventh aspect, the present disclosure provides a composition according to the first to third aspect for topical use. These and other aspects of the embodiments herein will be better appreciated and understood when considered in conjunction with the following description. It should be understood, however, that the following description, while indicating preferred embodiments and numerous specific details thereof, are given by way of illustration and not of limitation. Many changes and modifications may be made within the scope of the embodiments herein without departing from the spirit thereof, and the embodiments described herein include all such modifications. BRIEF DESCRIPTION OF THE DRAWINGS The invention is best understood from the following detailed description when read in conjunction with the accompanying drawings. It is emphasized that, according to common practice, the various features of the drawings are not to scale. On the contrary, the dimensions of the various features are arbitrarily expanded or reduced for clarity. Included in the drawings are the following figures: FIGURE 1 shows Improvement in Score of Physicians Global Aesthetic Improvement Scale (PGAIS) at Months 3 and 5 – mITT (modified Intent-to- Treat) Population. FIGURE 2 shows Improvement in Score of Subject's Global Aesthetic Improvement Scale (SGAIS) at Months 3 and 5 – mITT (modified Intent-to- Treat) Population. FIGURE 3 shows Subject Satisfaction Score (SSS) – mITT (modified Intent-to- Treat) Population. FIGURE 4 shows Wrinkle Severity Rating Scale (WSRS) – mITT (modified Intent-to-Treat) Population. FIGURE 5 shows Photographic improvement from baseline to the end of Month 5. FIGURE 6 shows Migration number of cells at 24 hrs (Groups 1a, 2a, 3a). FIGURE 7 shows Migration number of cells at 36 hrs (Groups 1a, 2a, 3a). FIGURE 8 shows Migration number of cells at 24 hrs (Groups 1b, 2b, 3b). FIGURE 9 shows Migration number of cells at 36 hrs (Groups 1b, 2b, 3b). FIGURE 10 shows Migration number of cells at 48 hrs (Groups 1b, 2b, 3b). FIGURE 11a shows Concentration of exosome particles per ml of GFC calculated by the nanoparticle tracking analysis (NTA) by FTLA Concentration / Size graph for Sample 1 from Table 6. FIGURE 11b shows Concentration of exosome particles per ml of GFC calculated by the nanoparticle tracking analysis (NTA) by Intensity / Size graph for Sample 1 from Table 6. FIGURE 12a shows Concentration of exosome particles per ml of GFC calculated by the nanoparticle tracking analysis (NTA) by FTLA Concentration / Size graph for Sample 25 from Table 6. FIGURE 12b shows Concentration of exosome particles per ml of GFC calculated by the nanoparticle tracking analysis (NTA) by Intensity / Size graph for Sample 25 from Table 6. FIGURE 13 shows Graphical representation of TGF β estimated values of stability samples against 4°C storage conditions at all stability study time points. FIGURE 14 shows Graphical representation of TGF β estimated values of stability samples against 25°C ± 2°C / 60 ± 5 % RH storage conditions at all stability study time points. FIGURE 15 shows Graphical representation of TGF β estimated values of stability samples against 30°C ± 2°C / 65 ± 5 % RH storage conditions at all stability study time points. FIGURE 16 shows Graphical representation of TGF β estimated values of stability samples against 40°C ± 2°C / 70 ± 5 % RH storage conditions at all stability study time points. FIGURE 17 shows Number of cells migrated after treatment with GFC and exosome depleted GFC at 1% and 2% concentrations. FIGURE 18A shows Comparison of cell migration on addition of 1% GFC and on supplementation of additional GFC exosomes (2X and 5X) to 1% GFC. The addition of exosomes enhances the migration capability of GFC. FIGURE 18B shows Comparison of cell migration on addition of 2% GFC and on supplementation of additional GFC exosomes (2X and 5X) to 2% GFC. The addition of exosomes enhances the migration capability of GFC. FIGURE 19 shows Cell migration on addition of GFC exosomes to basal medium (culture medium without FBS) greatly boosts the migration of fibroblasts even without FBS supplementation. Detailed description of the invention The publication discussed herein is provided solely for its disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. The inventors have surprisingly observed that the presence of exosomes in the growth factor concentrate composition works synergistically with growth factors. The embodiments described herein, and the various features and advantageous details thereof, are explained more fully with reference to the non- limiting embodiments that are detailed in the following description. Descriptions of well-known components and processing techniques are omitted so as to not unnecessarily obscure the embodiments herein. The examples used herein are intended merely to facilitate an understanding of ways in which the embodiments herein may be practiced and to further enable those of skill in the art to practice the embodiments herein. Accordingly, the examples should not be construed as limiting the scope of the embodiments herein. Reference will now be made to the exemplary embodiments, and specific language will be used herein to describe the same. It should nevertheless be understood that no limitation of the scope of the invention is thereby intended. Alterations and further modifications of the inventive features illustrated herein, and additional applications of the principles of the invention as illustrated herein, which would occur to one of ordinary skills in the relevant art and having possession of this disclosure, are to be considered within the scope of the invention. It must be noted that, as used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the content clearly dictates otherwise. All references including patents, patent applications, and literature cited in the specification are expressly incorporated herein by reference in their entirety. The term “medication” as used herein refers to a medicine or pharmaceutical drug, or simply drug; which is used to diagnose, cure, treat, or prevent disease. The term “medication” can also be refereed as the administration of a drug or medicine. The term “MYOWNN™” or “MYOWNN” as used herein refers to a trade nomenclature of applicants product of Autologous Growth Factor Concentrate (AGFC) containing face serum, the growth factors of which are obtained from volunteers own blood. This product is to be used for topical application for the purpose of anti-aging. The term “Autologous” as used herein refers to a situation in which the donor and recipient are the same person in blood transfusion and transplantation. The term “Face serum” as used herein refers to a lightweight, topical skin care product that contain a higher concentration of active ingredients, face serums are often used to manage specific skin care concerns. The term “ingredients” used in the present invention refers to pharmaceutical excipients routinely used in medicinal products. Typical, non- limiting examples of ingredients or excipients include Vehicle, Humectant (Moisturizing agent), Anti-oxidant, Skin lightening, Reducing Hyperpigmentation, Anti-ageing , Astringent agent, Anti-inflammatory agent, Humectant (Hydrating agent), pH balancer, Anti-oxidant, Thickener and stabilizer, Keratolytic agent (Anti-irritant), Thickening agent, and Deep penetration moisturizer (skin protectant). The most preferred vitamin C serum ingredients are Aqua, Glycerine, Ethyl Ascorbic Acid, Papaya Extract, Orange Extract, Licorice Extract, Niacinamide, Hyaluronic Acid, Citric Acid, Vitamin E Acetate, Xanthan Gum, Allantoin, Hydroxyethyl Cellulose, D Panthenol, Aloe Vera Extract and the like. Following are the aspects of the present disclosure. In a first aspect, the present disclosure provides a stable growth factor concentrate composition comprising: (a) growth factors; and (b) exosomes. In an embodiment of the first aspect described herein, the exosomes in the growth factor concentrate composition are growth factor concentrate (GFC) derived exosomes. In another embodiment of the first aspect described herein, the growth factors and exosomes in the growth factor concentrate composition are isolated from the human blood samples from healthy volunteers. In another embodiment of the first aspect described herein, the growth factors in the growth factor concentrate composition are acellular growth factors and are free of red blood cells (RBCs) and neutrophils. In another embodiment of the first aspect described herein, the analysed growth factors in the growth factor concentrate composition are Platelet Derived Growth Factor (PDGF), Transforming Growth Factor Beta (TGF-B), and Vascular Endothelial Growth Factor (V EGF). In another embodiment of the first aspect described herein, the growth factor concentrate composition further comprises a serum, preferably vitamin C serum, more preferably vitamin C serum comprising various ingredients. In another embodiment of the first aspect described herein, the growth factor concentrate composition further comprises a vitamin C serum, wherein the vitamin C serum in the growth factor concentrate composition comprises various ingredients that are one or more of Aqua, Glycerine, Ethyl Ascorbic Acid, Papaya Extract, Orange Extract, Licorice Extract, Niacinamide, Hyaluronic Acid, Citric Acid, Vitamin E Acetate, Xanthan Gum, Allantoin, Hydroxyethyl Cellulose, D Panthenol and Aloe Vera Extract. In a second aspect, the present disclosure provides a stable autologous growth factor concentrate composition comprising: (a) growth factors; (b) exosomes; and (c) vitamin C serum. In a third aspect, the present disclosure provides a stable face serum composition comprising: (a) growth factors; (b) exosomes; and (c) vitamin C serum. In another embodiment according to the first to third aspect described herein, the composition is stable for one or more from the following: (a) at least 12 months at 4°C, (b) at least 12 months at 25°C ± 2°C and a relative humidity of 60% ± 5 %, (c) at least 9 months at 30°C ± 2°C and a relative humidity of 65% ± 5 %, or (d) at least 6 months at 40°C ± 2°C and a relative humidity of 70% ± 5 %. In another embodiment according to the first to third aspect described herein, the exosomes are present at a concentration of 1x109exosomes / ml to 4.5 x1012exosomes / ml. In another embodiment according to the first to third aspect described herein, the exosomes are present at a concentration of 3.13×1010exosomes / ml to 4.25×1012exosomes / ml. In another embodiment according to the first to third aspect described herein, the exosomes are present in the composition at a concentration of about 3.13×1010exosomes / ml, 1.62×1011exosomes / ml, 2.30×1011exosomes / ml, 2.41×1011exosomes / ml, 2.59×1011exosomes / ml, 2.99×1011exosomes / ml, 3.06×1011exosomes / ml, 3.12×1011exosomes / ml, 3.25×1011exosomes / ml, 3.69×1011exosomes / ml, 4.07×1011exosomes / ml, 4.22×1011exosomes / ml, 4.42×1011exosomes / ml, 4.55×1011exosomes / ml, 4.56×1011exosomes / ml, 5.17×1011exosomes / ml, 5.50×1011exosomes / ml, 5.53×1011exosomes / ml, 5.73×1011exosomes / ml, 5.92×1011exosomes / ml, 6.62×1011exosomes / ml, 6.91×1011exosomes / ml, 8.25×1011exosomes / ml, 2.68×1012exosomes / ml, or 4.25×1012exosomes / ml. In a fourth aspect, the present disclosure provides a composition according to the first to third aspect for use as a medicament. In a fifth aspect, the present disclosure provides a composition according to the first to third aspect for use in maintaining healthy skin structure and function, for use in skin anti-aging or rejuvenation, or in the treatment of skin diseases. In a sixth aspect, the present disclosure provides a method of cosmetic treatment comprising applying a composition according to the first to third aspect to the skin of a human subject, preferably to the face of a human subject, preferably via topical administration. In a seventh aspect, the present disclosure provides a composition according to the first to third aspect for topical use. These and other aspects of the embodiments herein will be better appreciated and understood when considered in conjunction with the following description. It should be understood, however, that the following descriptions, while indicating preferred embodiments and numerous specific details thereof, are given by way of illustration and not of limitation. Many changes and modifications may be made within the scope of the embodiments herein without departing from the spirit thereof, and the embodiments described herein include all such modifications. While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the invention. Examples The present disclosure will be further described below in conjunction with specific embodiments, and the advantages and characteristics of the present disclosure will become clearer with the description. However, these embodiments are only exemplary and do not constitute any limitation to the scope of the present disclosure. Those skilled in the art should understand that the details and forms of the technical solutions of the present disclosure can be modified or replaced without departing from the spirit and scope of the present disclosure, but these modifications and replacements fall within the protection scope of the present disclosure. Example 1 A Prospective Multicenter Study to Evaluate the Safety and Efficacy of the Topical Application of MYOWNN™, an Autologous Growth Factor Concentrate (AGFC) Serum, in Anti-Aging. A study was designed to assess the safety and efficacy of a topically applied face serum - MYOWNN™ for anti-aging and facial rejuvenation. Materials and Methods: This study was conducted in accordance with globally accepted standards of Good Clinical Practice (GCP) (as defined in the ICH E6 Guideline for GCP), in agreement with the Declaration of Helsinki, and in keeping with local regulations. Ethics committee approvals were obtained from Wockhardt Hospitals Institutional Review Board (ECR / 624 / Inst / MH / 2014 / RR-17) and Cutis Institutional Ethics Committee (ECR / 930 / Inst / KA / 2017 / RR- 20). In the format of an open-label study, 50 subjects (26 female and 24 male) seeking facial skin rejuvenation with Fitzpatrick skin type III-V [Fitzpatrick TB: The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol. 1988, 6:869-71. 10.1001 / archderm.124.6.869] who have not taken any oral or topical treatments for at least four weeks before and any PRP-based treatment (injections) at least six months before the screening visit were recruited from two centers in India. Exclusion criteria were active acne, platelet count less than 150,000µl, known history of bleeding disorders or hemoglobinopathies, or history of systemic disease resulting in an immunocompromised state affecting the ability to heal soft tissue. Complete details of the study procedure were presented to all the subjects and written consent was obtained. For subjects who met the eligibility criteria and agreed to participate in the study, the facial assessment was done using Visage-LS (dermaindia®, Tamil Nadu, India) and a face analysis system; blood was collected for AGFC serum preparation. Demographic information, vital signs, and laboratory investigation were done to evaluate eligibility and safety during the study. Before application of the serum, subjects were instructed to wash their face, and if dryness was felt on the face, they were allowed to apply a moisturizer at least 20 minutes before the application of AGFC serum. However, in the case of oily skin, the use of a moisturizer was not recommended. Subjects were asked to apply a sunscreen lotion (at least 30 SPF) every three to four hours during the daytime for the entire study period. Subjects were instructed to avoid all kinds of cosmetic products, spa visits, any other facial treatment, and excessive exposure to sunlight during the study. Blood collected for AGFC preparation was sent to processing in break- proof packaging. Blood vacutainers were centrifuged to separate platelets and then activated by the activator consisting of sucrose + salt of calcium to get growth factor concentrate (GFC), which was extracted from the blood. Extracted GFC was transferred aseptically into sterile glass containers, which were then loaded in the lyophilizer. The lyophilization of GFC involved three basic steps, i.e., freezing, primary drying (sublimation), and secondary drying. Lyophilized GFC was then reconstituted with carrier serum and the permeabilizing agent to get the finished product. The finished product was shipped at 2-8°C to the study sites for a further dispensation to the subjects. AGFC serum was dispensed to the study subject for daily application. The subjects were instructed to do a local application on the face once daily at night, approximately 30 minutes before sleeping, preferably. The dispensed preparation was sufficient for topical application on the face once daily at bedtime for three months. At the end of 3 months, subjects were re-consented to evaluate their willingness to participate for additional 2 months i.e. till the end of five months. Out of 50 subjects, 36 agreed to participate for an additional two months and provided blood for AGFC preparation. All these subjects were followed up on a monthly basis till Month 3 and subjects who agreed to a re-bleed were followed till Month 5. At each monthly visit, subjects were evaluated for adverse events, concomitant medications, general facial examination, vital examination, treatment compliance since the last visit, and a facial assessment by the face analysis system. Objective analysis was performed by Visage-LS, a face analysis system, which is an advanced live status skin detection equipment together with shooting, analyzing, and displaying functions. It adopts the RGB (Red Blue Green), ultraviolet (UV), and polarized light (PL 3) spectrums combined with artificial intelligence and image analysis technology. It gives the live status of spots, pores, moisture, textures, wrinkles, and pigmentation. Subjective analysis was performed by globally accepted and validated scales like physician’s global aesthetic improvement scale (PGAIS), subject’s global aesthetic improvement scale (SGAIS), subject satisfaction score (SSS), and wrinkle severity rating scale (WSRS). PGAIS and SGAIS were scored from 1 to 5, with 1 being much worse, 2 being worse, 3 being no change, 4 being improved, and 5 being much improved. WSRS was scored from 1 to 5, with 1 being absent, 2 being mild, 3 being moderate, 4 being severe, and 5 being extreme. SSS were scored from 1 to 6, with 1 being very dissatisfied, 2 being dissatisfied, 3 being somewhat dissatisfied, 4 being somewhat satisfied, 5 being satisfied, and 6 being very satisfied. All statistical analysis was carried out using the SAS software, Version 9.4 (SAS Institute Inc., Cary, NC). The primary efficacy endpoint was computed as the average of six skin anti-aging parameters (spots, pores, wrinkles, texture, moisture, and pigmentation) measured by the face analysis system (Visage-LS). The secondary efficacy endpoints were the individual skin anti-aging parameters (spots, pores, wrinkles and texture, moisture, and pigmentation) from the face analysis system, PGAIS, SGAIS, SSS, and the photographic assessment (using the WSRS scale). A mixed model for repeated measures was used for this purpose. The model had change from baseline as the dependent variable visit as a factor and baseline assessment result as a covariate. All primary and secondary efficacy endpoints were analyzed using modified Intent-to-Treat (mITT) populations. Results: Out of the 50 subjects who were enrolled, 26 were female and 24 were male. The patients’ average age was 40 years, ranging from 30 to 55 years with a standard deviation of 8.62 years. According to the Fitzpatrick scale, 14 subjects (28%) had type III skin, whilst 27 patients (54%) had type IV and nine patients (18%) had type V skin. A total of five adverse events were reported during the study and none of these events were considered related to study treatment. These adverse events were erythema, hypothyroidism, coronavirus disease (COVID) infection, and two events of acne. There were no serious adverse events or treatment-related adverse events reported during the study, as well as no adverse events leading to study discontinuation. The results were analyzed from 47 subjects for Month 3 and 33 subjects for Month 5 who met the criteria for the mITT population. The mITT population included subjects who used at least one dose of study medication and had at least one post-baseline efficacy assessment. On statistical evaluation in the mITT population, there was a statistically significant percentage change in an average of six skin anti-aging parameters (spots, pores, wrinkles, texture, moisture, and pigmentation) from baseline to Month 5. The improvement in percentage change in an average of six skin anti- aging parameters started right from Month 3 (p-value of 0.1047) but significant improvement was seen by Month 5 (p-value of 0.0150) (Table 1). Table 1. Percentage Change in Average of Six Skin Rejuvenation Parameters - mITT Population Percentage Change from N Mean SD p-value * mITT – m A statistically significant percentage change in individual skin anti-aging parameters like moisture, texture, and wrinkles was also visible at Month 5 (with p-values of 0.0006, 0.0054, and 0.0007, respectively) (Table 2). Table 2. Percentage Change in Individual Skin Anti-aging Parameters - mITT Population Percentage Change from Mean SD p-value M i t r * * * * Baseline to Month 4 (Day 135) 12.6 33.38 0.0188* Baseline to Month 5 (Day 165) 17.5 28.78 0.0007* treat At the end of Month 5, the PGAIS maximum score of 4 or 5, i.e. improved or much improved, respectively, was reported in 100% of the cases (Figure 1), and on similar lines, the subjects also rated the SGAIS as the maximum score of 4 or 5, i.e. improved or much improved, respectively, in 100% of the cases (Figure 2). The subjects were asked to rate their satisfaction with SSS, whereupon at the end of Month 5, it was found that 12.12% of subjects were somewhat satisfied with the treatment, 84.85% subjects were satisfied, 3.03% subjects were very satisfied with the treatment, and none of the subjects were dissatisfied (Figure 3). On an assessment of WSRS, it was found that at least one point improvement in wrinkles was seen in 14.89% of cases at the end of Month 3, which improved to 37.5% and 48.48% at the end of Months 4 and 5 respectively (Table 3, Figure 4). Photographic improvement from baseline to the end of Month 5 is depicted in Figure 5. TABLE 3. Wrinkle Severity Rating Scale (WSRS) - mITT Population Score Category Description Month 3 Month 4 Month 5 (Day 105) (Day 135) (Day 165) %) ) Sensitivity analysis was also done to assess the efficacy parameters for the skin anti-aging parameters in subjects with age more than 50 years in the mITT population. The median percentage change from baseline to Month 3 (Day 105) was 4.1 compared to the median change in the overall population of 3.5, whereas the median percentage change from baseline to Month 5 (Day 165) was 7.3 compared to the median change seen in the overall population of 5.0. For the individual parameters like texture and wrinkles similar to the overall population and the trend in the median percentage change from baseline to Month 3 (Day 105) and Month 5 (Day 165) was seen. A statistically significant percentage change was seen in wrinkle parameters at Month 5 (p-value=0.0274) even with the small size (N=6) of this age population. For PGAIS and SGAIS assessment, at Month 5 (Day 165), all patients (6 (100.0%) of 6 patients) reported scores of 4 and 5. As per SSS, all patients were satisfied with the treatment at Month 3 (Day 105) and Month 5 (Day 165). For WSRS, at Month 5, five (83%) of six patients had scores between 1 and 3 and one (16.67%) of six patients had a score of 4; none of the subjects reported a score of 5. Discussion: Environmental factors and aging damage our skin and self-rejuvenation of the skin is supported by intrinsic growth factors that are generated by our own cells. As compared to young skin, aging skin generates fewer growth factors, which deems it necessary for the regular use of skin-care products with growth factors with the advancement of age basically to reduce the appearance of aging parameters like wrinkles, texture, fine lines, and tone [Aldag C, Nogueira Teixeira D, Leventhal PS: Skin rejuvenation using cosmetic products containing growth factors, cytokines, and matrikines: a review of the literature. Clin Cosmet Investig Dermatol.2016, 9:411-9.10.2147 / CCID.S116158]. The effects of three PRP injections over the course of 12 weeks were assessed on infraorbital wrinkles and skin tone in Asian subjects in a split-face study; this study showed significant improvement in both wrinkles and skin tone in infraorbital skin [Kang BK, Shin MK, Lee JH, Kim NI: Effects of platelet-rich plasma on wrinkles and skin tone in Asian lower eyelid skin: preliminary results from a prospective, randomised, split-face trial. Eur J Dermatol. 2014, 24:100-1. 10.1684 / ejd.2014.2267]. Dermaroller application of PRP over the subject’s malar area and forehead along with PRP injection into the wrinkles of crow’s feet biweekly for three times showed a statistically significant difference in skin firmness, wrinkles, and general appearance according to the grading scale of the patients before and after three PRP applications, whereas per the dermatologists, a statistically significant difference was seen only in skin firmness-sagging [Yuksel EP, Sahin G, Aydin F, Senturk N, Turanli AY: Evaluation of effects of platelet- rich plasma on human facial skin. J Cosmet Laser Ther. 2014, 16:206-8. 10.3109 / 14764172.2014.949274]. A limited number of controlled studies have been conducted to demonstrate that topically applied GFs can stimulate collagen synthesis and epidermal thickening, which is associated with clinical improvement in signs of photoaging. Also, very few studies have used objective analysis face systems to demonstrate improvement with the use of AGFC. In this study, both an objective analysis with a face analysis system like Visage-LS, as well as a subjective analysis with different globally accepted scales like PGAIS, SGAIS, SSS, and WSRS was performed with topical application of AGFC. In this open-label study, daily local application of AGFC over the face for three or five months showed a significant improvement in the average of six skin anti-aging parameters (spots, pores, wrinkles, texture, moisture, and pigmentation) from baseline. The improvement in percentage change in the average of six skin anti-aging parameters started right from Month 3 but significant improvement was seen by Month 5. A statistically significant percentage change in individual skin anti-aging parameters like moisture, texture, and wrinkles was also seen. There was a statistically significant improvement in skin texture at the end of five months of application with a p-value of 0.0054, whereas a similar statistically significant improvement was seen in moisture as early as the end of four months of application with a p-value of 0.0130, which further improved by the end of five months of application with a p-value of 0.0006. The fastest and earliest improvement in individual skin anti-aging parameters was seen in skin wrinkles; a statistically significant improvement in wrinkles was seen as early as the end of three months of application with a p-value of 0.0387, which was further improved by the end of four months of application with a p-value of 0.0188, whereas the most improvement in wrinkles was seen by the end of five months of application with a p-value of 0.0007. Similar improvement was seen in subjects with age more than 50 years, especially in individual parameters like texture and wrinkles. The study results are in line with other studies that have used injectable PRP, and our study also used an objective advanced face analysis system to assess the difference. There were no serious adverse events or treatment-related adverse events reported during the study as well as no adverse events leading to study discontinuation. There were no clinically meaningful laboratory- related changes observed and no clinically significant changes in vital signs parameters were observed during the study. This study had a few limitations like the relatively small sample size. Also, this was a non-comparative study but comparative studies are difficult to design in this indication, as variability in inter-individual skin conditions and skin aging factors is very high and can confound the results. Conclusions: Improvements in the average of six skin anti-aging parameters, as well individual parameters like wrinkles, moisture, and texture, depicted by objective analysis with a face analysis system were complemented by subjective analysis performed by different globally accepted scales like PGAIS, SGAIS, SSS, and WSRS. There were no safety concerns seen with the use of MYOWNN™ in this study, and long-term safety is being evaluated in an ongoing study. In conclusion, this study showed that topical MYOWNN™ treatment started showing a difference as early as three months with significant improvement by Month 5, and MYOWNN™ can be safely and effectively used for anti-aging and face rejuvenation. Example 2 Regenerative Potential Assessment of GFC composition In order to demonstrate the ability of presently claimed GFC composition a scratch assay was performed. In order to assess the regenerative potential of presently claimed GFC composition, an in-vitro cell migration study was performed. The 2D cell migration studies were performed on Human Fibroblasts that would mimic a human system. This study evaluated and compared the influence of presently claimed GFC composition (GFC + Exosomes + VIT C serum), GFC depleted of its own exosome component (GFC minus Exosomes + VIT C serum) and the carrier VIT C serum on human fibroblasts migration in a test system that mimics wound healing and cell migration in vitro. Vitamin C Serum This serum is basically used as vehicle, in which the GFC containing exosomes is mixed to make presently claimed GFC composition as a final product. The vitamin C Serum contains following ingredients: Ingredient Quantity Use / Role Aqua QS Vehicle es from healthy volunteers. The test was performed with GFC containing Exosomes (Group 1), GFC depleted of Exosomes (Group 2), and only VIT C serum (Group 3). The migration of human fibroblasts was evaluated with the scratch assay, and then recorded digital images were analysed by GIMP 2.10.24 software to compare the remaining artificial wound areas between the groups at 0, 24, 36 and 48 hours. This study evaluated and compared the influence of GFC having exosomes (Group 1) isolated from healthy human volunteers and GFC depleted of exosomes (Group 2) isolated from healthy human volunteers. The same volunteers samples were used for Group 1 and 2 to minimize variation and were also compared to the carrier VIT C serum (Group 3) on human fibroblasts migration in a test system that mimics wound healing and cell migration in vitro. GFC composition according to present invention has a very high viscosity. Direct application of GFC composition without any dilution would not yield any results due to the high viscosity. Hence, GFC composition was tested at two test combinations – 5% and 10%. GFC composition consists of 20% GFC (6ml GFC in 24ml base serum). Therefore, the actual concentration of GFC in the 5% test combination is 1% and in the 10% test combination is 2%. Wound healing scratch assays were conducted using 5% and 10% GFC composition as well as 1% and 2% GFC. To elucidate the role of exosomes in wound healing, exosome-depleted GFC was used for comparison at the same concentrations. TABLE 4. Study Groups Study Group Description Group 1a 5% GFC having Exosomes + VIT C serum St Group 1a: For every 95 ml of culture media, 5 ml of GFC having Exosomes added – 5%. This 5 ml of GFC having Exosomes was taken from a mixture of 6 ml GFC + 24 ml VitC Serum. Group 1b: For every 90 ml of culture media, 10 ml of GFC having Exosomes added – 10%. This 10 ml of GFC having Exosomes was taken from a mixture of 6 ml GFC + 24 ml VitC Serum. Group 2a: For every 95 ml of culture media, 5 ml of Exosome depleted GFC added – 5%, the exosome depletion was done by ultracentrifugation at 120,000 x g for 90 mins, thus removing the exosomes from the GFC. This 5 ml of Exosome depleted GFC was taken from a mixture of 6 ml GFC depleted of exosomes + 24 ml VitC Serum. Group 2b: For every 90 ml of culture media, 10 ml of Exosome depleted GFC added – 10%, the exosome depletion was done by ultracentrifugation at 120,000 x g for 90 mins, thus removing the exosomes from the GFC. This 10 ml of Exosome depleted GFC was taken from a mixture of 6 ml GFC depleted of exosomes + 24 ml VitC Serum. Group 3a: For every 95 ml of culture media, 5 ml of VIT C serum added – 5%. Group 3b: For every 90 ml of culture media, 10 ml of VIT C serum added – 10%. Results: All human fibroblasts that were cultivated in media with the above- mentioned groups (Groups 1-3) showed their ability to proliferate and migrate. Scratch assay showed human fibroblasts in the group 1 almost filled the artificial wound and showed greater migration of cells than in the group 2 and group 3 at 24, 36 and 48 hours, which was significant. Figure 6-10 displays migration number of cells for study groups from Table 4 at 24, 36 and 48 hours. TABLE 5. Migration number of cells at 24 hrs, 36 hrs and 48 hrs Study Group Number of cells migrated 24 hrs 36 hrs 48 hrs d d Co ulated by the nanoparticle tracking analysis (NTA) and presented in Table 6 (Figures 11 correspond to sample 1 and figure 12 correspond to sample 25). For illustration and as a specimen actual graph for sample 1 and sample 25 are shown in Figure 11 and 12. Similar graphs were obtained and the observed values for exosome concentrations are presented in Table 6. TABLE 6. Concentration of exosome particles per ml. Sample Particles / mlParticles / ml (Observed as)Reference Documents(Presented as) 15 4.56E+11 V12-A (12A) 2024-03-0612-36-574.56×101116 5.17E+11 V15-A (15A) 2024-03-0613-35-19 5.17×1011 Stability Data The real time & accelerated stability study of GFC composition according to present invention. The study with analysis was conducted up to 12 months to understand how the quality of product varies with the time under the influence of environmental factors such as temperature, humidity and packaging material which enables recommendation of storage conditions and shelf life to be established (Figures 13- 16). TABLE 7. SUMMARY / DETAILS OF THE STUDY CONDUCTED Physicochemical testing results: ID. Stor 0 1 2 3 4 6 9 12 h id w tly ous orm ion, cles id 4°CPalePale Pale Pale Pale Pale Pale Pale (2°ColorYellowYellow Yellow Yellow Yellow Yellow Yellow Yellow / 4 C Slightly Slightly Slightly Slightly Slightly Slightly Slightly Slightly ous orm ion, cles id tly ous or io cles id w tly ous or io cles id w tly ous orm id w tly ous R Uniform Uniform Uniform Uniform Uniform Uniform Uniform Uniform HUniformisolution, solution, solution, solution, solution, solution, solution, solution, no no no no no no no no cles id w tly ous or io cles id w tly ous or io cles id w tly ous orm ion, cles id w tly ous % Unifor Unifor Unifor Unifor Unifor Unifor Unifor Unifor R Uniformi m m m m m m m m H solutio solutio solutio solutio solutio solutio solutio solutio cles id w tly ous orm ion, cles id w tly ous orm ion, cles   TABLE 8. TGF‐β (Transforming Growth Factor Beta) estimation:                      Batch  Storage  h  580 unit 060 unit 820 unit 920 unit   25°C ± 2°C  /  60  291420 293940 287280 293580 296640 289620  284760  289260 2 / 25 D  unit 140 unit 860 unit 920 unit 860 unit 912 unit 942 unit 696 unit TABLE 9. Statistical analysis for GFC composition according to present invention in terms of TGF-β estimated values in all study time points:   01 Month  02 Month  03Month  04Month  06Month  09Month  12 Month  P‐Value  P‐Value  P‐Value  P‐Value  P‐Value  P‐Value  P‐Value  n      )      1  40°C ± 2°C  0.1048  0.4627  0.1848  0.1707  0.9994  <0.0001  <0.0001  /  70 ± 5 %  RH .   TABLE 10. Sterility verification for presence of bio-load: (Direct inoculation) Batch No’s Storage conditions 0 Month 12 Month l l l l l l l l l 1 / 40 D40°C ± 2°C / 70 ±5% RHNo evidence of microbial No evidence of microbial l l CONCLUSION Based on the stability study results of GFC composition according to present invention following are the major observations: A) There is no significant difference observed in physicochemical characteristics of the product throughout all the time point study with different environmental factors applied during the storage. B) With respect to TGF-β estimation, the study outcome observed from 0 to 12 month in different storage conditions are as below: 1. Storage at 4°C (2°C to 8°C): The P-value obtained with statistical analysis of TGF-β values up to 12 months shows no significant difference at this storage condition for all the study time points. 2. Storage at 25°C ± 2°C / 60 ± 5 % RH: The P-value obtained with statistical analysis of TGF-β values up to 12 months shows no significant difference at this storage condition for all the study time points. 3. Storage at 30°C ± 2°C / 65 ± 5 % RH: The P-value obtained with statistical analysis of TGF-β values up to 09 months shows no significant difference. However, there is a significant difference observed at 12 months TGF-β estimated values at this storage condition. 4. Storage at 40°C ± 2°C / 70 ± 5 % RH: The P-value obtained with statistical analysis of TGF-β values up to 06 months shows no significant difference. However, there is a significant difference observed at 09 & 12 months TGF-β estimated values at this storage condition. Hence, based on this stability study results below conclusions are derived: a) The product (GFC composition according to present invention) is stable at up to 12 months at 4°C (2°C to 8°C). And product shelf life can be assigned as 09 months at this storage condition. b) The product (GFC composition according to present invention) is stable at up to 12 months at 25°C ± 2°C / 60 ± 5 % RH. And product shelf life can be assigned as 09 months at this storage condition. Example 3 GFC and GFC-derived exosomes regenerative capabilities assessment using a 2D cell migration assay. Materials and Methods Growth factors concentrate (GFC) preparation GFC from 11 healthy individuals was prepared using the GFC kit after taking informed consent. The blood was processed to obtain GFC as per the manufacturer’s instructions. Briefly, 6 GFC kit tubes were collected from each volunteer, the blood was kept standing for 30 mins for platelet activation, the tubes were spun at 3,400 rpm for 10 min and the resulting GFC was collected. The GFC from the volunteers was pooled. Preparation of Exosome-depleted GFC and GFC exosomes The pooled GFC was centrifuged at 1,20,000 x g for 90 minutes at 4°C. This process yielded a pellet containing exosomes at the tube's bottom, while the remaining liquid, referred to as exosome-depleted GFC, was collected as supernatant. The supernatant was carefully removed and preserved, while the pellet was re-suspended in 1X phosphate-buffered saline (PBS). Cell lines For the present study, primary adult human dermal fibroblast was used. Human dermal fibroblasts (HDFs) were purchased from Gibco (Cat. No. C0135C; Gibco) and the cultures were established in Dulbecco’s Modified Eagle’s Medium (DMEM, Cat. No. 1033126; MP Biomedicals) with 10% Fetal Bovine Serum (FBS, Cat.No. 10270-106; Gibco) in 5% CO2, 95% humidified incubator at 37°C and passaged using Trypsin-EDTA buffer (Cat.No.25200-072; Gibco). Evaluation of influence of exosomes and GFC therapy on Migratory Capability of fibroblast cells using Scratch Test Assay The regenerative capabilities of GFC exosomes and GFC obtained through the GFC Kit were assessed using a 2D cell migration assay on cultured human dermal fibroblasts using the in vitro scratch wound healing assay. Cells are exposed to test compounds in the culture media, mimicking conditions akin to the wound healing process in vivo. Three distinct sets of experiments were conducted to elucidate and assess the influence of GFC and GFC exosomes on facilitating cell migration. Briefly, fibroblast cells were seeded into 24-well tissue culture plates (TPP) at a density of 55000 cells per well and cultured to confluence at 37˚C with 5% CO2. A small linear scratch was created in the confluent monolayer in each well by gently scraping it with a 200µl pipette tip. Cells were rinsed with sterile 1X PBS (Gibco) to remove any cellular debris before addition of various test combinations. The first set of experiment demonstrates the effect of GFC and GFC exosomes on promoting cell migration. In this, the scratched monolayers were treated with different test combinations prepared using GFC (1% and 2%) and exosome-depleted GFC (1% and 2%). Fibroblast culture medium containing 10% exosome-depleted FBS was used as ready-to-use (RTU) media (Figure 17). The second set of experiment was performed to demonstrate if supplementation of GFC with GFC exosomes accelerates cell migration. In this, the scratched monolayers were treated with test combination prepared using varying concentrations of GFC (1% and 2%) and GFC exosomes (2X and 5X), all prepared in RTU containing 10% exosome-depleted FBS. The average range of exosomes present in GFC is 8.05×1011exosomes / ml, accordingly, 2X (16.1×1011exosomes / ml) and 5X (40.25×1011exosomes / ml) concentrations were prepared (Figure 18A and Figure 18B). In experiment 3, the scratched monolayers were treated with different concentration of GFC exosomes (2X, 5X, 1011, 109and 107particles per ml) prepared in basal media without any FBS (Figure 19). The extent of healing was determined by the area covered by the cells migrating into the denuded area at the end of 18 hours and compared with the zero-hour time point. Imaging was performed using an Olympus CKX53SF Inverted Microscope, equipped with Magcam DC 5 camera and Magvision 4.6 software. The area covered by migrated cells was analyzed using the GNU Image Manipulation Program- GIMP 2.10.24 (revision 2). Observations and Results Table 11. Number of migrated cells in various study combinations No. of Study Combination migrated RTU – Ready to use media containing fibroblast culture medium + 10% exosome- depleted FBS Basal – Fibroblast culture media without the addition of FBS GFC – Growth Factor Concentrate Exosomes / Exo – Exosomes isolated from GFC Details of combinations – Experiment 1 I. 1% GFC in RTU = RTU media containing 10% exosome-depleted FBS, added with 1% GFC (this GFC contains exosomes, the natural range of exosomes in serum on average is 1011exosomes / ml) II. 2% GFC in RTU = RTU media containing 10% exosome depleted FBS, added with 2% GFC (this GFC contains exosomes, the natural range of exosomes in serum on average is 1011exosomes / ml) III. 1% Exo-depleted GFC in RTU = RTU media containing 10% exosome- depleted FBS, added with 1% exosome-depleted GFC (this GFC does not contains exosomes; exosomes were removed by ultra-centrifugation of GFC at 1,20,000 x g for 90 mins, this removes exosomes, the supernatant is GFC depleted of exosomes) IV. 2% Exo-depleted GFC in RTU = RTU media containing 10% exosome- depleted FBS, added with 2% exosome-depleted GFC (this GFC does not contains exosomes; exosomes were removed by ultra-centrifugation of GFC at 1,20,000 x g for 90 mins, this removes exosomes, the supernatant is GFC depleted of exosomes) Experiment 2 I. 1% GFC + 2X Exosomes in RTU = RTU media containing 10% exosome- depleted FBS, added with 1% GFC and additional 2X GFC-derived exosomes (the normal range of exosomes from the GFC obtained is 8.05×1011exosomes / ml, therefore 2X exosomes is 16.1×1011exosomes / ml) II. 2% GFC + 2X Exosomes in RTU = RTU media containing 10% exosome- depleted FBS, added with 2% GFC and additional 2X GFC-derived exosomes (the normal range of exosomes from the GFC obtained is 8.05×1011exosomes / ml, therefore 2X exosomes is 16.1×1011exosomes / ml) III. 1% GFC + 5X Exosomes in RTU = RTU media containing 10% exosome- depleted FBS, added with 1% GFC and additional 5X GFC-derived exosomes (the normal range of exosomes from the GFC obtained is 8.05×1011exosomes / ml, therefore 5X exosomes is 40.25×1011exosomes / ml) IV. 2% GFC + 5X Exosomes in RTU = RTU media containing 10% exosome depleted FBS, added with 2% GFC and additional 5X GFC-derived exosomes (the normal range of exosomes from the GFC obtained is 8.05×1011exosomes / ml, therefore 5X exosomes is 40.25×1011exosomes / ml) Experiment 3 I. 5X Exosomes in Basal = Basal media (this is cell culture media without the addition of FBS), to the basal media 5X GFC exosomes per ml added (40.25×1011exosomes / ml) II. 2X Exosomes in Basal = Basal media (this is cell culture media without the addition of FBS), to the basal media 2X GFC exosomes per ml added (16.1×1011exosomes / ml) III. 1X / 1011Exosomes in Basal = Basal media (this is cell culture media without the addition of FBS), to the basal media 1011GFC exosomes per ml added (8.05×1011exosomes / ml) IV. 109Exosomes in Basal = Basal media (this is cell culture media without the addition of FBS), to the basal media 109GFC exosomes per ml added (8.05×109exosomes / ml) V. 107Exosomes in Basal = Basal media (this is cell culture media without the addition of FBS), to the basal media 107GFC exosomes per ml added (8.05×107exosomes / ml) The experimental results are analyzed on four parameters as provided below: 1. Effect of GFC concentration: Increasing the concentration of GFC in RTU generally leads to an increase in the number of migrated cells. For example, the number of migrated cells increases from 196 to 231 when going from 1% to 2% GFC in RTU. 2. Effect of exosomes: Adding exosomes at varying concentrations to 1% and 2% of GFC in RTU shows an increase in the number of migrated cells with increase in exosome concentration. 3. Effect of exosome-depleted GFC: Comparing GFC with and without exosomes (exosome-depleted GFC), it appears that the presence of exosomes influences the number of migrated cells. For example, 1% GFC in RTU leads to 196 migrated cells, while 1% exo-depleted GFC in RTU leads to 180 migrated cells. Normal GFC (GFC containing exosomes) shows a higher number of migrated cells inferring better healing as compared to depletion of exosomes from GFC which resulted in lower number of migrated cells, therefore indicating that GFC containing exosomes enhances healing. 4. Effect of exosomes in basal media: Adding exosomes to basal media leads to an increase in the number of migrated cells, with higher concentrations of exosomes resulting in more significant increases. This indicates the importance of exosomes in healing. Overall, these observations suggest that both the concentration of GFC, and the presence of exosomes significantly influence the migration of cells. The results provide insights into the complex interplay between growth factors, exosomes, and cellular behavior in the experimental system. This also indicates that GFC composition according to present invention containing normal GFC (GFC containing exosomes) would enhance cell migration indicating better regeneration of fibroblasts in the skin. These experiments demonstrates the ability of growth factor concentrate (GFC) and GFC exosomes derived from GFC kit to promote regenerative capacity as assessed by cell migration using the scratch wound healing assay. When GFC was added to culture medium of fibroblasts an increase in number of fibroblast cells migrating in the denuded area was observed in a concentration-dependent manner. When GFC was supplemented with additional GFC exosomes, a further increase in migration was observed indicating that GFC exosomes contribute in promoting cell migration. In another experiment, GFC exosomes were added to basal culture medium without FBS or any other growth-promoting serum. An increase in cell migration proportional to the concentration of added exosomes was observed. The results of this experiment are a further corroboration that exosomes play a crucial role in aiding cell migration. Overall, the above data demonstrates encouraging evidence for the role of GFC and GFC exosomes in healing and rejuvenation which needs to be explored further.

Claims

We Claim:

1. A stable growth factor concentrate composition comprising: (a) growth factors; and (b) exosomes.

2. The composition as claimed in Claim 1, wherein the exosomes are growth factor concentrate (GFC) derived exosomes.

3. The composition as claimed in Claim 1, wherein the growth factors and exosomes are isolated from the human blood samples from healthy volunteers.

4. The composition as claimed in Claim 1, wherein the growth factors are acellular growth factors and are free of red blood cells (RBCs) and neutrophils.

5. The composition as claimed in Claim 1, wherein the analysed growth factors are Platelet Derived Growth Factor (PDGF), Transforming Growth Factor Beta (TGF-B), and Vascular Endothelial Growth Factor (V EGF).

6. The composition as claimed in Claim 1, further comprise a serum.

7. The composition as claimed in Claim 6, wherein serum is vitamin C serum.

8. The composition as claimed in Claim 7, wherein the vitamin C serum comprises various ingredients.

9. The composition as claimed in Claim 8, wherein the vitamin C serum ingredients are one or more of Aqua, Glycerine, Ethyl Ascorbic Acid, Papaya Extract, Orange Extract, Licorice Extract, Niacinamide, Hyaluronic Acid, Citric Acid, Vitamin E Acetate, Xanthan Gum, Allantoin, Hydroxyethyl Cellulose and D Panthenol.

10. A stable autologous growth factor concentrate composition comprising: (a) growth factors; (b) exosomes; and (c) vitamin C serum.

11. A stable face serum composition comprising: (a) growth factors; (b) exosomes; and (c) vitamin C serum.

12. The composition as claimed in claims 1 to 11, wherein the composition is stable for one or more from the following: (a) at least 12 months at 4°C, (b) at least 12 months at 25°C ± 2°C and a relative humidity of 60% ± 5 %, (c) at least 9 months at 30°C ± 2°C and a relative humidity of 65% ± 5 %, or (d) at least 6 months at 40°C ± 2°C and a relative humidity of 70% ± 5 %.

13. The composition as claimed in claims 1 to 11, wherein the exosomes are present at a concentration of 1x109exosomes / ml to 4.5 x1012exosomes / ml.

14. The composition as claimed in claims 1 to 11, wherein the exosomes are present at a concentration of 3.13×1010exosomes / ml to 4.25×1012exosomes / ml.

15. The composition as claimed in claims 1 to 11, wherein the exosomes are present in the composition at a concentration of about 3.13×1010exosomes / ml, 1.62×1011exosomes / ml, 2.30×1011exosomes / ml, 2.41×1011exosomes / ml, 2.59×1011exosomes / ml, 2.99×1011exosomes / ml, 3.06×1011exosomes / ml, 3.12×1011exosomes / ml, 3.25×1011exosomes / ml, 3.69×1011exosomes / ml, 4.07×1011exosomes / ml, 4.22×1011exosomes / ml, 4.42×1011exosomes / ml, 4.55×1011exosomes / ml, 4.56×1011exosomes / ml, 5.17×1011exosomes / ml, 5.50×1011exosomes / ml, 5.53×1011exosomes / ml, 5.73×1011exosomes / ml, 5.92×1011exosomes / ml, 6.62×1011exosomes / ml, 6.91×1011exosomes / ml, 8.25×1011exosomes / ml, 2.68×1012exosomes / ml, or 4.25×1012exosomes / ml.

Citation Information

Patent Citations

  • Methods and compositions for treating lung conditions

    WO2022018729A1